| scholarly article | Q13442814 |
| P50 | author | Francesco Bertolini | Q56850281 |
| Stefania Orecchioni | Q56992583 | ||
| Martine Daujat-Chavanieu | Q59690301 | ||
| Nerea Allende-Vega | Q64788606 | ||
| P2093 | author name string | Javier Hernandez | |
| Catherine Alexia | |||
| Guillaume Cartron | |||
| Giovanna Talarico | |||
| Dang-Nghiem Vo | |||
| Delphine Gitenay | |||
| Abrar Ul Haq Khan | |||
| Claire Gondeau | |||
| Sana Belkahla | |||
| Martin Villalba Gonzalez | |||
| P2860 | cites work | Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells | Q71254201 |
| Human hepatocyte culture | Q83830231 | ||
| An integrated encyclopedia of DNA elements in the human genome | Q22122150 | ||
| BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C | Q24532869 | ||
| Interaction of myocyte enhancer factor 2 (MEF2) with a mitogen-activated protein kinase, ERK5/BMK1 | Q24548255 | ||
| Role of dichloroacetate in the treatment of genetic mitochondrial diseases | Q24630740 | ||
| Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer | Q24652941 | ||
| Big mitogen-activated kinase regulates multiple members of the MEF2 protein family | Q28137985 | ||
| Metabolic modulation of glioblastoma with dichloroacetate | Q28282255 | ||
| p53 mutations in human cancers | Q28302973 | ||
| Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer | Q28487677 | ||
| Chemical metabolic inhibitors for the treatment of blood-borne cancers | Q28822335 | ||
| Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy | Q33186850 | ||
| ERK5 is a novel type of mitogen-activated protein kinase containing a transcriptional activation domain | Q33605384 | ||
| HIF-1α inhibition reverses multidrug resistance in colon cancer cells via downregulation of MDR1/P-glycoprotein | Q33717131 | ||
| Nrf2 upregulates ATP binding cassette transporter expression and activity at the blood-brain and blood-spinal cord barriers | Q33770428 | ||
| The ABC transporter structure and mechanism: perspectives on recent research. | Q33977051 | ||
| Sodium dichloroacetate exhibits anti-leukemic activity in B-chronic lymphocytic leukemia (B-CLL) and synergizes with the p53 activator Nutlin-3. | Q34100963 | ||
| Evidence that glutamine, not sugar, is the major energy source for cultured HeLa cells | Q34205774 | ||
| The NF-κB member p65 controls glutamine metabolism through miR-23a. | Q34277479 | ||
| Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells | Q34297004 | ||
| Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. | Q34303662 | ||
| Cancer chemoresistance: the relationship between p53 and multidrug transporters | Q34580489 | ||
| Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells | Q34989395 | ||
| MHC-I modulation due to changes in tumor cell metabolism regulates tumor sensitivity to CTL and NK cells | Q35201839 | ||
| Dichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation | Q35232780 | ||
| Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics. | Q35538527 | ||
| Transcriptional regulation of ABC drug transporters | Q35567283 | ||
| Dichloroacetate | Q36189244 | ||
| The presence of wild type p53 in hematological cancers improves the efficacy of combinational therapy targeting metabolism | Q36326369 | ||
| Human Leukemic Cells performing Oxidative Phosphorylation (OXPHOS) Generate an Antioxidant Response Independently of Reactive Oxygen species (ROS) Production | Q36538773 | ||
| Nuclear respiratory factor 1 controls myocyte enhancer factor 2A transcription to provide a mechanism for coordinate expression of respiratory chain subunits | Q36585576 | ||
| Frequent mutations in the p53 tumor suppressor gene in human leukemia T-cell lines | Q36729673 | ||
| Availability and applications of ATP-binding cassette (ABC) transporter blockers | Q36830826 | ||
| Daunorubicin and gambogic acid coloaded cysteamine-CdTe quantum dots minimizing the multidrug resistance of lymphoma in vitro and in vivo | Q37361842 | ||
| Lack of ABCG2 Leads to Biventricular Dysfunction and Remodeling in Response to Hypoxia | Q37653867 | ||
| p53 regulation of metabolic pathways | Q37746471 | ||
| The Role of p53 in Metabolic Regulation | Q37903700 | ||
| From tumor cell metabolism to tumor immune escape | Q38008488 | ||
| New insight into p-glycoprotein as a drug target | Q38038886 | ||
| p53 mutations in cancer | Q38069463 | ||
| Mutant p53 in cancer: new functions and therapeutic opportunities | Q38197826 | ||
| The pharmacology of dichloroacetate | Q38300732 | ||
| Metformin combined with sodium dichloroacetate promotes B leukemic cell death by suppressing anti-apoptotic protein Mcl-1. | Q38787624 | ||
| MRP4 (ABCC4) as a potential pharmacologic target for cardiovascular disease. | Q38804190 | ||
| Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine | Q38908007 | ||
| Diverse relations between ABC transporters and lipids: An overview | Q38969762 | ||
| Oxidative phosphorylation induces de novo expression of the MHC class I in tumor cells through the ERK5 pathway. | Q39664735 | ||
| ERK5 activates NF-kappaB in leukemic T cells and is essential for their growth in vivo. | Q40206582 | ||
| Global gene expression analysis of ERK5 and ERK1/2 signaling reveals a role for HIF-1 in ERK5-mediated responses. | Q40273686 | ||
| MEK5/ERK5 signaling inhibition increases colon cancer cell sensitivity to 5-fluorouracil through a p53-dependent mechanism | Q41610131 | ||
| The PDK1 Inhibitor Dichloroacetate Controls Cholesterol Homeostasis Through the ERK5/MEF2 Pathway | Q41632623 | ||
| Glycolysis in P-glycoprotein-overexpressing human tumor cell lines. Effects of resistance-modifying agents | Q41945970 | ||
| SUMOylation regulates the transcriptional activity of JunB in T lymphocytes. | Q46634753 | ||
| Sensitization of breast cancer cells to paclitaxel by dichloroacetate through inhibiting autophagy | Q48799695 | ||
| ABCA3 deficiency presenting as persistent pulmonary hypertension of the newborn | Q50335632 | ||
| Extracellular-signal-regulated kinase 5 modulates the antioxidant response by transcriptionally controlling Sirtuin 1 expression in leukemic cells. | Q54348750 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1114-1129 | |
| P577 | publication date | 2017-12-14 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Changes in metabolism affect expression of ABC transporters through ERK5 and depending on p53 status | |
| P478 | volume | 9 |
| Q91896726 | Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications |
| Q61796855 | MEK5/ERK5 activation regulates colon cancer stem-like cell properties |
| Q89576023 | Phospho-PTM proteomic discovery of novel EPO- modulated kinases and phosphatases, including PTPN18 as a positive regulator of EPOR/JAK2 Signaling |
| Q59329958 | Sodium Dichloroacetate Pharmacological Effect as Related to Na-K-2Cl Cotransporter Inhibition in Rats |
| Q55002919 | p53 and metabolism: from mechanism to therapeutics. |
Search more.